Metabolomics-assisted evaluation of differences and clinical value between ablation and surgical treatment for lung adenocarcinoma - Takeaways - MDSpire

Metabolomics-assisted evaluation of differences and clinical value between ablation and surgical treatment for lung adenocarcinoma

  • By

  • Youli Wen

  • Yang Zeng

  • Wenqiang Li

  • Xinyu Deng

  • Wu Qunhua

  • Zhiping Deng

  • July 16, 2026

Share

  • 1

    The study compared metabolic impacts and clinical benefits of ablation and surgical approaches in 40 lung adenocarcinoma patients.

  • 2

    Metabolomic profiling identified distinct metabolic networks, achieving effective group separation using supervised OPLS-DA models.

  • 3

    Ablation demonstrated superior diagnostic efficacy (AUC = 0.79) compared to traditional imaging (0.75) and biochemical tests (0.65).

  • 4

    Clinical assessment showed ablation resulted in shorter hospital stays, reduced costs, and fewer complications while maintaining equivalent pulmonary function.

  • 5

    The integration of metabolomics with traditional methods enhanced diagnostic power (AUC = 0.85), supporting optimized therapeutic decision-making.

Original Source(s)

Metabolomics-assisted evaluation of differences and clinical value between ablation and surgical treatment for lung adenocarcinoma

  • by Youli Wen, Yang Zeng, Wenqiang Li, Xinyu Deng, Wu Qunhua, Zhiping Deng

  • July 16, 2026

Related Content

Outcomes following different thermal ablation strategies in patients with oligometastatic colorectal lung metastases

Distribution and function of human long-lasting T cells in aging and non-small cell lung cancer

A prehabilitation-enhanced nomogram for predicting early pulmonary recovery failure after lung tumor surgery: development and multicenter validation